Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The <scp>Meet‐Uro 19BEYOND</scp> study-Reference-Cited by-同舟云学术

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study

Published:2022-03-20 Issue:16 Volume:11 Page:3084-3092
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Roviello Giandomenico¹^ORCID,Gambale Elisabetta²,Giorgione Roberta²,Santini Daniele³,Stellato Marco³,Fornarini Giuseppe⁴,Rebuzzi Sara Elena⁵⁶,Basso Umberto⁷,Bimbatti Davide⁷,Doni Laura²,Nesi Gabriella¹,Bersanelli Melissa⁸,Buti Sebastiano⁸,De Giorgi Ugo⁹,Galli Luca¹⁰,Sbrana Andrea¹¹,Conca Raffaele¹²,Carella Claudia¹³,Naglieri Emanuele¹³,Pignata Sandro¹⁴,Procopio Giuseppe¹⁵^ORCID,Antonuzzo Lorenzo²¹⁶^ORCID

Affiliation:

1. Department of Health Sciences University of Florence Florence Italy

2. Medical Oncology Unit Careggi University Hospital Florence Italy

3. Department of Medical Oncology University Campus Bio‐Medico Rome Italy

4. Medical Oncology Unit 1 IRCCS Ospedale Policlinico San Martino di Genova Genoa Italy

5. Medical Oncology Unit San Paolo General Hospital Savona Italy

6. Department of Internal Medicine and Medical Specialties (Di.M.I.) University of Genova Genoa Italy

7. MedicalOncology Unit 1 Istituto Oncologico Veneto IOV IRCCS Padua Italy

8. Medical Oncology Unit University Hospital of Parma Parma Italy

9. IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Italy

10. Medical Oncology Unit 2 Azienda Ospedaliero‐Universitaria Pisana Pisa Italy

11. Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine University of Pisa Pisa Italy

12. Division of Medical Oncology, Department of Onco‐Hematology IRCCS‐CROB, Referral Cancer Center of Basilicata Rionero in Vulture Italy

13. Istituto Oncologico Giovanni Paolo II Bari Italy

14. Department of Urology and Gynecology Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Naples Italy

15. Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy

16. Department of Experimental and Clinical Medicine University of Florence Florence Italy

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4681

Reference32 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies

3. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

4. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

5. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review;Cancer Treatment Reviews;2024-01

2. Abscopal effect with fever of unknown cause during radiotherapy: Two case reports and review of the literature;Experimental and Therapeutic Medicine;2023-09-18

3. Engineering cytokines for cancer immunotherapy: a systematic review;Frontiers in Immunology;2023-07-06